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Abstract 
Malaria is the leading cause of morbidity and mortality in Sub-Saharan Africa. One key strategic intervention is provision of 
early diagnosis and prompt effective treatment. A major setback has been the development of drug resistance to commonly 
used antimalarials. To overcome this, most countries in Sub-Saharan Africa have adopted Artemisinin Combination Therapy 
(ACT) as a first line treatment for uncomplicated malaria. Artemether Lumefantrine (AL) and Artesunate Amodiaquine (ASAQ) 
are the main drugs of choice. There are key implementation issues, which may have a bearing on the scaling up of this new 
treatment. This article reviewed the published papers on ACT with focus on sustainability, compliance, and diagnosis. ACTs  
are costly, but highly effective. Their scaling up is the most cost effective malaria intervention currently available. Most 
countries rely heavily on the Global Fund for their scaling up. AL has a short shelf life, a complicated six-dose regimen that 
requires intake with fat to ensure sufficient bioavailability. High rates of adherence have been reported. Use of parasitic 
diagnosis is advocated to ensure rational use. Parasitic diagnostics like rapid test and microscopy are currently inadequate. 
The majority of malaria cases may continue to be diagnosed clinically leading to over prescription of drugs. ACTs are currently 
not available at the community level for home based management of malaria. Issues related to safety and rational use need 
to be addressed before their use in the informal health sector like community drug sellers and community health workers. The 
majority of malaria cases at the community level could go untreated or continue to be treated using less effective drugs. We 
conclude that ACTs are highly effective. A major challenge is ensuring rational use and access at the household level. It is 
hoped that addressing these issues will increase the likelihood that ACT achieves its intended goals of reducing morbidity and 
mortality due to malaria, and delaying the onset of drug resistance. 
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Malaria Burden 
Malaria can be an acute or a chronic disease. It is 
caused by intracellular protozoa of the genus Plasmodium 
that are transmitted by the bite of an infected female 
Anopheles mosquito. Anopheles gambiae is the most 
important vector in Africa and is among the most efficient 
for transmission of the disease [1]. There are 120 
Plasmodium species, of which four are of consequences to 
humans: P. falciparum, P. vivax, P. malariae and P. ovale. 
These share a common basic life cycle, though there are 
differences in their pathogenicity and epidemiology. It is P. 
falciparum which causes nearly all the mortality in cases of 
malaria infection [1,2]. 
 
Globally, it is estimated that one million children die 
from malaria annually [1,2,3]. An estimated 90% of all 
global deaths due to malaria occur in Sub-Saharan Africa 
[2,4]. Children under five and pregnant women are most 
at risk. It is estimated that malaria accounts for 30-50% of 
inpatient admissions and 50% of total outpatient visits in 
children under five [3], and nearly 25% of all childhood 
mortality in Africa [4]. Malaria has been linked to poverty 
[5]. It has slowed economic growth in African countries by 
1.3% per year resulting in a gross domestic product which  
is 32% lower than  it would have been had malaria been 
eradicated from Africa in 1960. Malaria accounts for 40% 
of public health expenditure and is estimated to cost Africa 
more than US$ 12 billion every year in lost GDP [5]. 
 
 
Global response 
In 1998, the World Health Organisation, the United 
Nations Children’s Fund (UNICEF), the United Nations 
Development Programme (UNDP), and the World Bank 
joined forces to create the Roll Back Malaria Partnership 
(RBM). The aim of this initiative is to reduce malaria 
mortality by 50% by the year 2010 and achieve the 
malaria-related Millennium Development Goals (MDGs) by 
2015. This partnership has increased with the addition of a 
wide range of partners. The mission of the RBM is to 
enable sustained delivery and use of the most effective 
prevention and treatment interventions for those affected 
most by malaria [6]. These interventions include use of 
insecticide treated nets, vector control, indoor residual 
spraying, presumptive treatment of pregnant women and 
prompt effective treatment of malaria cases. 
 
In Sub-Saharan Africa, malaria has for a long time been 
treated using cheap and effective drugs like Chloroquine, 
Sulphadioxine pyrimethamine, and Amodiaquine. The 
malaria parasite has gradually developed resistance to 
these drugs, decreasing their effectiveness. A study in a 
holoendemic area in western Kenya in 1993 found a 
resistance of 35% to Amodiaquine and 34.5% to 
Sulphadioxine pyrimethamine [7]. WHO recommends  a 
change in the first line treatment if total failure proportion 
exceeds 10% [8]. Many countries have adopted 
Artemisinin Combination Therapy (ACT) as the first line 
drugs for the treatment of uncomplicated malaria. 
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The objectives of any national malaria treatment policy 
is to provide access to safe, good quality, effective, 
affordable, and acceptable antimalarial drugs; ensure 
rapid and long lasting cure, and delay development of 
resistance to antimalarial drugs. ACT partly fits this bill as 
they are highly efficacious but costly. An open label study 
in Kenya, Tanzania, and Nigeria assessed the efficacy and 
safety of ACT in infants and children with acute, 
uncomplicated falciparum malaria showed that treatment 
was safe and well tolerated with an overall 28-day cure 
rate of 86.5% and 93.9% when corrected by Polymerase 
Chain Reaction for re-infection [9]. The aim of the study 
was to explore and highlight potential implementation 
issues in the scaling up of ACTs with more emphasis on 
artemether-lumefantrine, as the first line anti-malaria 
treatment in Sub-Saharan Africa, and the study focused on 
the key implementation issues e.g. sustainability, access, 
and compliance with regard to the scaling up of ACT in 
Sub-Saharan Africa. 
 
Rationale for Implementation research 
It has been argued that implementation research should 
not stop after demonstration of proof that an intervention 
is efficacious. Implementation research should go further 
and solve major implementation problems. 
Implementation research is borne out of the realisation 
that many interventions have been successfully 
researched and developed, and yet had little impact due 
to implementation issues. The overall goal of 
implementation research is to significantly improve access 
to efficacious interventions against tropical diseases by 
developing practical solutions to common critical problems 
in the implementation of these interventions [9]. 
 
Combination Therapy 
Combination therapy is not a new phenomenon. It has 
been deployed in the treatment of diseases like TB, 
leprosy, and AIDS. It delays emergence of resistance and 
increases efficacy [10]. Antimalarial combination therapy is 
the simultaneous use of two or more blood schizontocidal 
drugs with independent modes of action and thus 
unrelated biochemical targets [8]. Artemisinin and its 
derivatives (Artesunate, Artemether, Artemotil, and 
Dihydro-Artemisinin) produce rapid clearance of 
parasitaemia and rapid resolution of symptoms. They 
reduce parasite numbers by a factor of 10-100 times when 
compared to other antimalarials. Artemisinin compounds 
are active against all the four species of Plasmodium that 
infect humans [8]. 
 
A public health advantage of ACT is that they reduce 
gametocyte carriage and thus transmissibility of malaria 
[1]. This plays a prominent role in malaria control in areas 
of low transmission, though this may not be so in areas of 
high transmission intensity where a large reservoir exists 
in asymptomatic people [1]. A major  potentially serious 
adverse effect reported with ACT is type I hypersensitivity 
reactions in approximately 1 in 3,000 patients [12], 
though phase IV trials are yet to be carried out and the 
possibility of other adverse reactions cannot be ruled out 
[13]. WHO currently recommends four ACTs. These are 
Artemether-Lumefantrine, Artesunate + Amodiaquine, 
Artesunate + mefloquine, and Artesunate + Sulfadoxine-
pyrimethamine. The choice of ACT depends on the level of 
resistance of the partner drug in the combination and 
transmission intensity [8.[ 
Artemether- lumefantrine 
Artemether- lumefantrine is one of the ACT drugs being 
used by most countries in sub-Saharan Africa. It was the 
first ACT available in combination dose and whose 
manufacturer, Novartis Pharma, has been vetted by WHO 
as having good manufacturing practices.  It is a 
combination of the Artemisinin derivative: Artemether and 
Lumefantrine (previously called benflumetol) in a 1:6 ratio. 
It is a new, effective, and well-tolerated drug [14]. It 
achieves its antimalarial effect through the initial large 
reduction in parasite biomass by artemether and 
subsequent removal of all the remaining viable parasites 
by the less active but more slowly eliminated lumefantrine 
[15]. The combination also provides mutual protection of 
the two antimalarial drugs from the development of 
resistance, as parasites are never exposed to artemether 
alone and relatively few are exposed to lumefantrine [15]. 
 
Overall cure depends on the presence of adequate 
lumefantrine to eradicate residual biomass left by 
artemether, and this in turn is reliant on adequate 
bioavailability. The oral bioavailability of lumefantrine is 
reduced significantly in the acute phase of malaria. 
Patients with acute malaria are reluctant to eat and often 
vomit. The more severe the infection, the less likely the 
will to eat.  Lumefantrine is poorly water-soluble and 
highly lipophilic [16]. Oral bioavailability increases 
substantially after a meal rich in fat. A healthy volunteer 
study compared absorption in fasted subjects and subjects 
who took the drug with a high-fat meal showed that 
artemether bioavailability increased two-fold and 
Lumefantrine bioavailability increased 16-fold in those who 
took the drug with food [16]. Ashley et al conducted a 
multiple crossover pharmacokinetic study to compare the 
area under the plasma concentration-time curve (AUC) for 
lumefantrine after administration of a single dose of AL in 
fasting state with varying amounts of fat. The population 
means estimated the volume of Soya milk required to 
obtain 90% of maximum effect (in terms of lumefantrine 
AUC)  to be 36 milliters or 1.2 grams of fat [17]. This will 
be a challenge in the scaling up of ACTs  since  achieving  
high cure rates requires the achievement of sufficient 
bioavailability.   Ensuring consistent intake with a fatty 
meal in unsupervised settings may not be easy. To 
increase lumefantrine absorption, doses should be taken 
at the required intervals accompanied by food.  An interval 
of 8 hours between the first and the second dose, 24 
hours between the first and the third dose, and 12 hourly 
intervals between doses thereafter is recommended. 
 
Diagnosis of malaria 
Microscopy
Light microscopy is the most efficient method for 
parasitological diagnosis of malaria. It is done by 
examining a stained thick or thin blood smear for the 
presence of malaria parasites. Thin films are 
recommended for species identification. Light microscopy 
is considered to be the ‘gold standard’ against which the 
sensitivity and specificity of other methods must be 
assessed [18]. A skilled microscopist is able to detect 
asexual parasites of densities of fewer than 10 parasites 
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per micro litre of blood but under typical field conditions 
the limit of sensitivity is approximately 100 parasites per 
micro litre of blood [18]. Light microscopy has important 
advantages. These include low direct costs if the 
infrastructure to maintain the service is available; high 
sensitivity if the quality of microscopy is high; it can 
differentiate between plasmodia species; it can determine 
parasite species and can be used to diagnose many other 
conditions [8]. There are constraints to ensuring good 
quality microscopy. These include inadequate training and 
supervision of laboratory staff; the need to rely on 
electricity at night time; delays in providing results to 
patients and the need for maintaining quality assurance 
and control of laboratory services [8]. 
 
In research set ups, the quality of microscopy is quite 
high.  A sensitivity of 99.6% and a specificity of 100% 
have been attained [19]. In non-research settings, 
diagnostic accuracy varies. A cross-sectional survey to 
evaluate accuracy of routine malaria microscopy was 
conducted in 17 health facilities found in two districts in 
Kenya. After comparing initial microscopy readings to 
expert readings, the sensitivity and specificity of routine 
microscopy was 68.6% and 61.5% respectively. The 
positive predictive value was 21.6% and negative 
predictive value 92.7% [20]. 
 
Microscopy can play a key role in promoting rational use 
of ACT because it enables the clinicians to distinguish 
febrile episodes caused by the malaria parasite from those 
arising from other causes. In a prospective study in 
Uganda, use of microscopy and withholding antimalarial 
therapy in febrile children with negative blood smears was 
found to be safe and saved over 1600 antimalarial 
treatments in 601 children over an 18 month period [19]. 
In Kenya microscopy is not widely available. It has been 
estimated that functional microscopy exists only in 24% of 
all government health facilities [20]. In Zambia, 
microscopy was found to be available at 39% of health 
facilities [21]. Malaria treatment guidelines by WHO, state 
that in high malaria endemic areas, any child with fever or 
history of fever is presumptively classified and treated as 
malaria. Parasitological diagnosis is not a pre-requisite. In 
low malaria endemic areas, any child with fever or history 
of fever in the absence of measles, running nose or any 
other identifiable cause of fever is to be presumptively 
classified and treated as having malaria. Use of 
parasitological diagnosis is recommended. In all patients 
aged 5 years or above with fever or history of fever, the 
use of parasitological diagnosis is recommended. Where 
diagnostics are lacking, presumptive treatment is carried 
out [8]. 
 
Rapid diagnostic tests (RDTs) 
RDTs are immunochromatographic tests based on 
detection of specific parasite antigens, either Plasmodium 
lactate dehydrogenase (pLDH) activity or the presence of 
Histidine-Rich-Protein (HRP). Most of the RDTs available 
are specific for Plasmodium falciparum. RDTs are simple to 
use and are sensitive in detecting low parasitaemia [4]. 
Use of RDTs is not recommended for follow up, as most of 
the tests remain positive for up to 2 weeks following 
effective antimalarial and clearance of parasites. They also 
cannot be used to determine parasite density [4], and 
they are relatively more expensive than microscopy. Their 
key advantage is that they can be used in a wide range of 
setups from hospitals to field laboratories, users require 
minimal training compared to microscopy, and can be 
taught to low cadre workers [8]. Some RDTs are 
susceptible to heat induced damage and may not perform 
well under the high temperatures prevalent in the tropics 
[22]. Most manufacturers of RDTs recommend that their 
products be stored at temperatures below 30 °C. These 
recommendations may not be maintained during the 
shipment and use of RDTs in field labs. 
 
Clinical diagnosis 
Clinical diagnosis is through the detection of signs and 
symptoms. These include fever, chills, headache and 
anorexia. These per se are not specific to malaria but 
apply to many diseases. Clinical diagnosis if not 
supplemented by parasitological diagnosis, tends to 
overestimate malaria cases. A review by Amexo et al. 
found that clinical diagnosis by health professionals 
overestimates malaria (number of cases with negative 
microscopy over the number of malaria clinical diagnosis) 
by an average of 61%, ranging from 28% to 96% [23]. 
Among children, bacterial diseases tend to be 
misdiagnosed as malaria and in one study bacterial 
diseases may have been responsible for more deaths in 
children than malaria in a malaria endemic area [24]. In a 
prospective study in Kampala, malaria was responsible for 
only 32% of febrile episodes in children [19]. A study in 
Kenya found out that the children had an average of 
around 7 episodes of fever per year, of which only 2.5 
were due to malaria [25]. This leads to children being 
treated for the wrong diseases which could be harmful. 
One study concluded that the probability of dying was two 
times higher in children diagnosed to have malaria but 
with a negative blood slide compared to those with a 
positive blood slide [26]. One factor leading to an 
overestimate of malaria among adults in some areas is the 
prevalence of HIV/AIDS. A study in Malawi found that 
fever was much more likely to be associated with HIV 
infection than with malaria parasitaemia [27].  There have 
been attempts to develop clinical algorithms, with limited 
success as a review that their use in highly endemic areas 
resulted in a high risk of failure to treat malaria. The best 
clinical algorithms were site specific [28]. 
 
Diagnostics
Clinical diagnosis without any parasitological diagnosis 
has been the norm in many African countries. In the 
advent of ACT this has to change. Presumptive treatment 
may only be acceptable in children under 5 years. Studies 
have shown that there is a three fold higher rate of 
malaria cases among children aged 0-4 years compared to 
those aged 5- 14 years [1]. In Kwa Zulu Natal (KZN), AL 
was introduced in 2000 (29). Prior to this, rapid 
immunochromatographic card tests were introduced in 
1996 to ensure definitive malaria diagnosis in all public-
sector health-care facilities. Thus only definitive cases 
were treated in KZN and this was a major factor in 
attaining the estimated cost savings of US$ 201,065 in 
2002 alone for the sub- district studied [29]. In most 
countries, both ACT and malaria related diagnostic tests 
are being scaled up simultaneously and overdiagnosis 
cannot be ruled out. Provision of diagnostics must be 
accompanied by adequate quality control. This is 
considering that high temperatures may affect RDTs. A 
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study in Kenya found that microscopy in government 
health facilities had  positive predictive values (21.6%). 
This means that four out of every five slides reported as 
positive were indeed negative [20]. A major challenge is 
scaling up diagnostics concurrently with ACTs and 
ensuring quality control is maintained. 
 
Changing prescribing patterns
Changing clinicians’ prescribing patterns after transition 
to a new drug is also a challenge. Zambia was the first 
African country to change its policy towards using more 
expensive Artemether-Lumefantrine (AL), characterised by 
a ‘complex dosing regimen, complicated procurement and 
distribution; and little national prescribing experience’ 
[21]. A study was done to evaluate treatment practices for 
uncomplicated malaria after the policy change in 4 
districts. Among children weighing 10 kilograms or more, 
Sulphadoxine pyrimethamine (SP) was commonly 
prescribed (68%) whereas the recommended AL was 
prescribed for only 11% of children. Among children 
weighing more than 10 kilograms seen at facilities where 
AL was available, AL was prescribed for 22% of children 
and SP for 54% [21].  A follow-up survey two years later 
found significant improvements in malaria case 
management. The proportion of children weighing 5-9 
kilograms treated with AL rose from 1% to 27%, and from 
11% to 42% among those weighing 10 kilograms or more 
[30]. 
A study in Kenya indicated that 79.3% of patients with a 
negative result were treated for malaria [20]. Studies have 
shown that in the midst of this over-prescription at health 
facilities, there are genuine malaria cases that are 
misdiagnosed and subsequently not treated for malaria.  A 
study in Zambia estimated this to comprise 17% of 
children with uncomplicated malaria, and 18% in Kenya   
[21]. Changing clinicians prescribing behaviour is possible 
but requires investment to ensure adequate quality 
assurance, regular training and supervision [31]. 
 
Adherence to ACTs 
A study done on adherence to a six-dose Artemether-
lumefantrine regimen found that adherence was high at 
90% [32]. Lack of formal education was the only factor 
associated with non-adherence after controlling for 
confounders (odds ratio = 3.1) and the most commonly 
missed dose was the sixth dose (41.7%). A study on 
adherence in a refugee settlement in Zambia found higher 
rates of non-adherence, with 60.6% of patients probably 
non-adherent. Non adherence was highly associated with 
insufficient explanation by the dispenser [33]. This study 
used strict definitions and a patient who took all tablets 
was classified probably non-adherent if the day of intake 
was incorrect. The drugs were also given out in loose 
sachets [33]. A study on adherence to AL in southern 
Sudan found that 18.3% of patients were non-adherent 
[34].  In another study, high cure rates irrespective of 
whether AL was given under supervision with food or 
under conditions of routine clinic practice were observed. 
Day-28 cure rates were 97.7% and 98.0% in the 
supervised and unsupervised groups, respectively [35]. A 
study in Tanzania found that complete adherence 
measured at 48 hours was 75.0%, based on self-report 
and tablet counts [36]. Counselling by health workers is 
important as it plays a key role in ensuring adherence. 
This is more so given the need for fat intake to ensure 
sufficient bioavailability. AL comes already pre-packaged in 
blister packs, which contain pictorial instructions on how 
to take the drug. This is intended to discourage resale and 
improve compliance, as non-literate people will be able to 
follow instructions. A potential problem is that the rapid 
resolution of symptoms may make some patients 
discontinue treatment and save the remaining drugs for 
future use. In one study, 13.7% of caretakers stopped 
treatment once the child appeared to have recovered [33]. 
 
Use of ACT in home management of malaria (HMM) 
In Africa, the majority of malaria cases are treated 
outside the formal health sector. This is because provision 
of health services is inhibited by factors like inadequate 
funds, drug stock-outs, inaccessibility, poor management 
and demoralized staff. In addition, optimal utilization of 
services is hampered by the relationships between 
providers and clients [37]. This leads to government 
health facilities being underutilized, for example in Mali the 
utilization rate is 0.15 new cases per inhabitant per year, 
Ivory Coast 0.12 and Benin 0.24 [38].  Home Management 
of Malaria (HMM) is an intervention geared towards 
improving access to antimalarial treatment close to 
homes. It includes training both health staff, community 
members, a campaign for behavioural change, and the 
production and distribution of user friendly, pre packaged 
drugs at community level. It utilises trained community 
based agents (CBA) who treat febrile cases using the pre-
packaged medicines. CBA include community health 
workers, shopkeepers and teachers. In Kenya, the training 
of shopkeepers led to an increase in the proportion of over 
the counter drug users receiving an adequate dose from 
8% in 1998 to 64% in 2001(39). HMM plays a key role in 
attaining one of the targets of roll back Malaria, which is 
60% of people with malaria have access to effective drugs 
within 24 hours of onset of symptoms [40]. In Kenya, it 
was estimated that only 5.3% of fevers in children under 5 
years were treated with an antimalarial drug within the 
first 24 hours, and only 2.3% were treated with SP which 
was the recommended drug then [41]. HMM has been 
proven to be effective. In an often quoted study in 
Ethiopia, mother co-ordinators were trained to teach other 
local mothers on recognition of malaria symptoms and to 
promptly give choloroquine. Under 5 mortality declined by 
40% in the intervention localities [42]. 
 
The use of ACT in HMM is currently a contentious issue. 
The above mention study from Ethiopia in support of 
HMM, was done in an area of low, seasonal malaria 
transmission. Tigray area also has an effective community 
based primary health care programme characterised by 
frequent supervision of Community Health Workers 
(42,43(what are these numbers?  Some experts have 
argued it should not be used as the negative 
consequences will outweigh benefits. These include poor 
compliance, over-prescription and cost implications [43]. 
Amanua et al found use of AL to be feasible and 
acceptable in Ghana with 92.5% of children  being treated 
with an adequate dose of AL, and delay in seeking 
treatment declined from  3 to 2 days after onset of 
symptoms [44]. Though such an intervention cannot be 
implemented on a large scale as this intervention was 
carried out for only four months, supervision was high and 
the number of children treated was low. The authors did 
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note that for the program to be sustainable the 
Community based Agents (CBAs) need to be paid. 
 
ACT is given by prescription only and is not available 
over the counter. Thus it cannot be sold by informal 
sellers like shopkeepers [45]. AL is being provided free of 
charge at health facilities and this creates no incentive for 
shopkeepers to stock such a drug, even if it was possible 
for them to do so.  Health education including mass media 
campaigns are being utilised to persuade people to go for 
treatment directly at the health facilities, the underlying 
assumption being that they are accessible. This will in 
effect create a two-tier drug system, with the ACTs being 
available in health facilities and less effective antimalarials 
being available at the community and household levels 
[46]. 
 
Sustainability of ACT treatment 
Cost has been cited as a major impediment in the 
scaling up of ACT [47,48], with ACTs costing close to ten 
times more than other antimalarials.  Introduction of AL in 
Zambia was estimated to have caused a six fold increase 
in the amount of funds normally spent on the purchase of 
antimalarials, and use of AL was estimated to result in an 
incremental cost-effectiveness ratio of US$4.10 compared 
to SP [48]. 
In 2002, the US Agency for International Development 
commissioned the Institute of Medicine (IOM) to 
recommend global actions to ensure the broadest possible 
access to ACT. In a report issued in 2004, the IOM 
Committee on Economics of Antimalarial drugs 
recommended a global subsidy of US$ 300- 500 million 
per year to replace the increasingly ineffective drugs with 
coformulated ACT therapies. This international subsidy 
would discourage the distribution of monotherapies, such 
as solo artemisinins. This would prevent the development 
of drug resistance to ACT [49]. In 2001, WHO entered into 
a special pricing  agreement with Novartis, in which 
Coartem® will be made available at a negotiated price 
ranging from US$ 0•9  in the smallest children to US$2•40 
for an adult course. These prices represent the production 
costs only incurred by Novartis and are subject to periodic 
reviews to ensure that they constantly reflect production 
costs only [50]. The drug comes pre-packaged in a blister 
pack. There are 4-age specific blister packs, which contain 
6, 12, 18 or 24 tablets respectively, according to the 6-
dose regimen recommended by WHO. This agreement 
allows Novartis to forecast demand and plan production 
schedules more efficiently [50]. This is important as the 
artemisinin component is derived from the plant Artemisia 
annua. The cycle of planting, harvesting, extraction of 
artemisinin and further processing to Artemether requires 
10 months. Novartis requires a period of 4 months from 
the time it receives an order from WHO to when it ships 
the product, though a 6 months period is recommended 
[50]. 
 
The Global Fund to Fight AIDS, Tuberculosis and Malaria 
(GFATM) is the financial engine behind the scaling up of 
ACT [18,22]. Since the establishment of the GFATM in 
2002, a total of US$ 230 million have been allocated for 
malaria programmes, mainly for the procurement of ACTs, 
and mostly for African countries. The GFATM grants 
enable countries to scale up their fight against malaria. 
These grants enable the countries to purchase ACTs 
directly or indirectly through WHO which acts as a broker 
[45,50]. Most countries rely heavily on the Global Fund to 
implement this new treatment. Delays in cash flow after 
grant approval has led to 43 countries adopting ACT but 
only nine implementing it by 2005 [47]. Sustainability of 
the treatment has been questioned. Kenya, for example, 
typically spends 10 million US dollars on essential drugs in 
one year [11]. The annual cost of ACT required is over 
twice this amount. In 2006, the Global Fund announced 
that a new round of funding (Round 6) could be 
jeopardized by lack of finances [40]. At the global level, 
other sources of funding are available and may facilitate 
scaling up of ACT.  These include the World Bank’s 
Booster Programme for Malaria Control, which amounts to 
between US$500 million and US$1 billion over the next 
five years, and USA’s President’s Malaria Initiative (PMI) 
for US$1.2 billion over five years for 15 countries [6]. This 
is good, though relying on donor support for long term 
financial support may not augur well for sustained scaling 
up [47,48]. 
 
The drug is single sourced, as WHO only prequalified 
Novartis as the sole manufacturer. This was aimed at 
ensuring quality and avoiding counterfeit drugs, which 
account for 25% of all drugs in developing countries [51]. 
On the other hand, it leaves no room for cheaper generics 
or competitive bidding, which is contrary to public 
procurement rules [45]. This also locks out local 
pharmaceutical companies from this lucrative market 
despite Artemisia annua being grown in these countries 
[45,47]. AL has a short shelf life of 2 years and Novartis 
normally freights the drug. This is cost-effective, as it 
allows the drug to have at least 18 months lead time 
before expiry. If the drug was manufactured locally, they 
would be savings on the freight charges and more lead 
time to expiry.  The logistics in place should ensure 
effective distribution so as to avoid the drugs running out 
or expiring [50]. In Zambia 8% of health facilities had in 
their possession expired AL and they also suffered from 
stock-outs 30% of the time [21]. 
 
The patent for Coartem expires in 2010 and is held by 
Novartis, though Cipla does manufacture artemether and 
lumefantrine in bulk but not in combination. Other less 
expensive ACTs are currently being developed. In March 
2007, Drugs for Neglected Diseases Initiative and Sanofi 
Aventis Pharmaceuticals launched a less expensive ACT, 
artesunate Amodiaquine (ASAQ). An adult dose costs 
US$1 dollar and a child dose costs US$ 0.5. It also has a 
simple dosing formula compared to AL as an adult takes 
only two tablets a day and a child one tablet. ASAQ is not 
patented and is a cheaper but still effective alternative to 
AL [52.[ 
 
Cost effectiveness of ACT 
Despite being costly, ACT was found to be the most cost 
effective strategy for control of malaria in most countries 
in sub-Saharan Africa with a net effectiveness of 63% 
reduction in case fatality [53]. Muheki et al explored the 
economic aspects of the implementation of Artemether-
Lumefantrine to replace SP in the Kwa Zulu Natal province 
in South Africa. The number of outpatient malaria cases 
and inpatient admissions both declined by 94% between 
2000 and 2002. After accounting for the role of concurrent 
improvements in vector control, it was conservatively 
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estimated that 36% of the decline in outpatient cases and 
46% for inpatient admissions was attributable to changing 
the first line drug to AL [29]. 
 
A cost-effectiveness study of antimalarial combinations 
in Tanzania found AL to be the most cost-effective. From a 
societal perspective AL was most cost-effective at day 14; 
resulting in a gross saving of US$1.51 or a net saving of 
US$22.24 per case averted [54]. In Zambia, the average 
cost-effectiveness ratio, defined as the total treatment 
cost divided by the total number of cases successfully 
treated (i.e. cost per cured case), has been estimated at 
US$8.57 and US$10.65 for AL and SP respectively [48]. 
 
ACT has a high cure rate thus relatively fewer patients 
will develop complicated malaria. This results in cost 
savings due to decline in hospital admissions and 
treatments using expensive second line drugs.  This 
superiority comes with a price. This extra or incremental 
cost of producing one extra successful cure of an episode 
of malaria is known as the incremental cost-effectiveness 
ratio, which was estimated to be US$4.10 [48]. This is the 
amount that it costs to achieve one extra successfully 
treated case using AL in relation to Sulphadoxine 
pyrimethamine. 
 
It has been argued that there is a need to shift from a 
narrow disease based focus to comprehensive integrated 
health services. This will make health services more 
accessible and will facilitate better malaria control [55]. 
 
Conclusion
Donor funding is fickle and may not prove reliable in the 
long run, therefore governments must increase their 
health sector funding in line with the Abuja declaration so 
as to attain a minimum 15% of total government 
expenditure. This will enable them to cover for any 
shortfalls in the donor funding. Single sourcing is bad for 
prices and runs contrary to public sector procurement 
rules. This has to be done away with and there is hope 
that Chinese and Indian pharmaceutical firms will produce 
cheaper ACT’s. 
There is need to strengthen health systems by better 
disease prevention and control and finding new ways of 
treatment, to secure less resistance and better effect for 
the drugs. 
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